Business
Azenta Reports First Quarter Results for Fiscal 2025, Ended December 31, 2024
BURLINGTON, Mass., Feb. 5, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2024.
About this update from Azenta, Inc.
[{"type":"text","content":"BURLINGTON, Mass., Feb. 5, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2024.\nThe results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the fourth fiscal quarter of 2024 of its intention to pursue a sale.\nQuarter Ended\nDollars in millions, except per share data\nDecember 31,\nSeptember 30,\nDecember 31,\nChange\n2024\n2024\n2023\nPrior Qtr\nPrior Yr.\nRevenue from Continuing Operations\n$\n148\n$\n151\n$\n142\n(2)\n%\n4\n%\nOrganic growth\n4\n%\nSample Management Solutions\n$\n81\n$\n85\n$\n79\n(4)\n%\n3\n%\nMultiomics\n$\n66\n$\n66\n$\n63\n0\n%\n6\n%\nDiluted EPS Continuing Operations\n$\n(0.21)\n$\n(0.00)\n$\n(0.13)\nNM\n(63)\n%\nDiluted EPS Total\n$\n(0.29)\n$\n(0.10)\n$\n(0.28)\nNM\n(5)\n%\nNon-GAAP Diluted EPS Continuing Operations\n$\n0.08\n$\n0.22\n$\n0.08\n(64)\n%\n(1)\n%\nAdjusted EBITDA - Continuing Operations\n$\n13\n$\n18\n$\n7\n(25)\n%\n89\n%\nAdjusted EBITDA Margin - Continuing Operations\n9.0\n%\n11.8\n%\n5.0\n%\nManagement Comments\"Our first quarter results represent a strong start to fiscal 2025 as we see positive momentum in the demand for our unique offering of Sample Management Solutions and Multiomics services,\" stated John Marotta, President and CEO. \"Starting the year like this gives us confidence in the strength of our unique market positioning, value proposition and ability to continue evolving to our customers' needs while delivering profitable growth. We continue to see the benefit of our transformation initiatives and our free cash flow was strong. We are encouraged by the progress we are making.\"\nFirst Quarter Fiscal 2025 Results - Continuing Operations\nRevenue was $148 million, up 4% year over year. Organic revenue, which excludes a nominal impact from foreign exchange, was also up 4% year over year. The year-over-year revenue increase was attributable to higher Multiomics and Sample Management Solutions revenues. Sample Management Solutions revenue was $81 million, up 3% year over year.Organic revenue grew 2%, mainly driven by higher revenues in Sample Repository Solutions and Core Products, particularly in Consumables and Instruments and Clinical and Cryogenic Stores Systems.Multiomics revenue was $66 million, up 6% year ov...